Jim Slattery
Overview
Explore the profile of Jim Slattery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Slattery J, Quinten C, Candore G, Pinheiro L, Flynn R, Kurz X, et al.
Br J Clin Pharmacol
. 2022 Apr;
88(10):4526-4539.
PMID: 35483963
Aims: The objective of this study was to describe ondansetron drug utilization patterns during pregnancy to treat nausea and vomiting in pregnancy (NVP). Moreover, we aimed to describe the maternal...
2.
Candore G, Monzon S, Slattery J, Piccolo L, Postigo R, Xurz X, et al.
Drug Saf
. 2021 Dec;
45(1):83-95.
PMID: 34881404
Introduction And Objective: European Union legislation has mandated the submission of European Economic Area non-serious reports to the EudraVigilance database since November 2017. As spontaneous reports of suspected adverse reactions...
3.
Hedenmalm K, Pacurariu A, Slattery J, Kurz X, Candore G, Flynn R
Drug Saf
. 2021 Jul;
44(9):973-985.
PMID: 34273099
Introduction: The analgesic metamizole, which has been withdrawn from the market in several countries due to the risk of agranulocytosis but is still available on the market in Germany and...
4.
Segec A, Slattery J, Morales D, Januskiene J, Kurz X, Arlett P
Pharmacoepidemiol Drug Saf
. 2020 Nov;
30(3):350-359.
PMID: 33197106
Purpose: To evaluate the impact of including a medicine in the list of medicinal products subject to additional monitoring (AM) on the reporting of adverse drug reactions (ADRs) in the...
5.
Januskiene J, Segec A, Slattery J, Genov G, Plueschke K, Kurz X, et al.
Pharmacoepidemiol Drug Saf
. 2020 Oct;
30(3):334-341.
PMID: 33099846
Background: The additional monitoring (AM)/black triangle concept is aimed to enhance ADR reporting for certain types of medicinal products for which the safety profile is less well established. Purpose: The...
6.
Slattery J, Kurz X
Pharmacoepidemiol Drug Saf
. 2020 Apr;
29(10):1336-1340.
PMID: 32301230
Before a medicine can be recommended for a marketing authorization research must be provided to regulators that convincingly supports the benefit-risk of the product in the claimed indication. The established...
7.
Gini R, Sturkenboom M, Sultana J, Cave A, Landi A, Pacurariu A, et al.
Clin Pharmacol Ther
. 2020 Apr;
108(2):228-235.
PMID: 32243569
Although postmarketing studies conducted in population-based databases often contain information on patients in the order of millions, they can still be underpowered if outcomes or exposure of interest is rare,...
8.
Morales D, Pacurariu A, Slattery J, Kurz X
Br J Clin Pharmacol
. 2020 Feb;
86(7):1336-1345.
PMID: 32068906
Aims: Hydrochlorothiazide-induced photosensitivity may increase squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and lip cancer risk. The aim was to quantify these risks. Methods: Nested case-control studies using data...
9.
Candore G, Hedenmalm K, Slattery J, Cave A, Kurz X, Arlett P
Clin Pharmacol Ther
. 2020 Jan;
107(4):915-925.
PMID: 31956997
Exploring and combining results from more than one real-world data (RWD) source might be necessary in order to explore variability and demonstrate generalizability of the results or for regulatory requirements....
10.
Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X
JAMA Neurol
. 2019 Apr;
76(7):827-833.
PMID: 31034074
Importance: Peripheral neuropathy has been associated with systemic fluoroquinolone exposure, but risk has been poorly quantified. Objective: To calculate relative and absolute risk estimates for the association of fluoroquinolone exposure...